Detection and prevention of maculopathy associated with antimalarial agents

International Ophthalmology Clinics

Volumn 39, Issue 2, 1999, Pages 49-57

  Easterbrook, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE;

COLOR VISION TEST; CRITICAL FLICKER FUSION; DOSE CALCULATION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALARIA; PERIMETRY; PRIORITY JOURNAL; RETINA MACULOPATHY; REVIEW; RISK FACTOR; VISUAL ACUITY; VISUAL FIELD;

ANTIMALARIALS; CHLOROQUINE; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; HUMANS; HYDROXYCHLOROQUINE; MACULA LUTEA; RETINAL DISEASES;

EID: 0032900483     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-199903920-00005     Document Type: Review

References (33)

1. Cambioggi A. Unusual ocular lesions in a case of systemic lupus erythematosis. Arch Ophthalmol 1957;57:451-453
2. Easterbrook M. Is corneal deposition of antimalarials any indication of retinal toxicity? Can J Ophthalmol 1990;25:249-256
3. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med 1988;85(symp 4A):23-29
4. Percival SPB, Behrman J. Ophthalmological safety of chloroquine. Br J Ophthalmol 1969;53:101-109
5. Reynes R. Ophthalmologic considerations in using antimalarials in the United States. Lupus 1996;5(suppl 1):S73-S74
6. Royal College of Ophthalmologists. Ocular toxicity and hydroxychloroquine. Guidelines for screening. 1998
7. Nozik RA, Weinstock F, Vignos P Jr. Ocular complications of chloroquine. Am J Ophthalmol 1964;58:774-778
8. Carr R. Chloroquine and organic changes in the eye. Dis Nerv Syst 1968; 29(suppl):36-39
9. Vu L, Easterbrook M. Color vision testing in patients treated with antimalarials with proven macular toxicity [abstract]. Trans Am Acad Ophthalmol (in press)
10. Cruess AF, Schachet AP, Nicholl J, et al. Chloroquine retinopathy: is fluorescein angiography necessary? Ophthalmology 1985;92:1127-1129
11. Cortin P, Fontaine R. Study of critical flicker fusion frequency in chloroquine retinopathy. In: Proceedings of the Canadian Ophthalmological Society Meeting, Montreal, Canada, June 23, 1981
12. Easterbrook M. The use of Amsler grids in early chloroquine retinopathy. Ophthalmology 1984;91:1368-1372
13. Easterbrook M. The sensitivity of the Amsler grid in early chloroquine retinopathy. Trans Ophthalmol Soc UK 1985;104:204-207
14. Easterbrook M, Trope G. Visual field testing in detection of early chloroquine retinopathy. In: Proceedings of the annual meeting of the Association for Research in Vision and Ophthalmology, Sarasota, FL, May 5, 1988
15. Easterbrook M. Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 1992;27:237-239
16. Easterbrook M, Bernstein H. New guidelines for ocular monitoring based on risk-free periods for chloroquine and hydroxychloroquine retinopathy. In: Proceedings of the annual meeting of the American Academy of Ophthalmology, San Francisco, Cal, October 29, 1997
17. MacKenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983;75:40-45
18. Easterbrook M. Current concepts in monitoring patients on antimalarials [editorial]. Aust NZ J Ophthalmol 1998;26:101-103
19. Metropolitan Life Insurance Company. Metropolitan Life Insurance tables. New York: Metropolitan Life Insurance Company, 1983
20. Morsman CDG, Liversey SJ, Richards IM, et al. Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye 1990;4:572-576
21. Morand EF, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1992;51:1318-1321
22. Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40: 1482-1486
23. Levy GD. Hydroxychloroquine ocular toxicity [letter]. J Rheumatol 1998;25:1030
24. Spalton DJ. Retinopathy and antimalarial drugs - the British experience. Lupus 1996; 5(Suppl 1) S70-S72
25. Block JO. Hydroxychloroquine and retinal safety. Lancet 1998;351:771
26. Blyth C, Lane C. Hydroxychloroquine retinopathy: is screening necessary? Br Med J 1998;916:710-727
27. Mavrikakis M, Papazoglou S, Saikiakis P, et al. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996;55:187-189
28. Bernstein H. Safety of antimalarials. In: Proceedings of the annual meeting of the American Academy of Ophthalmology, Dallas, TX, November 1992
29. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal-dose therapy. Ann Ophthalmol 1993;25:385-388
30. Weiser A, Sandberg MA, Gaadio AR, et al. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991;121:582-584
31. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology clinic. Ann Rheumatol Dis 1997;56:188-190
32. Raines MF, Bhargava SK, Rosea GS. The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci 1998;30:1726-1731
33. Easterbrook M. An ophthalmological view on the efficacy and safety of chlorquine vs. hydroxychloroquine. J Rheumatol (in press)